Vaxart to Participate at Upcoming Conferences
11 Novembro 2021 - 6:01PM
Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu,
President and CEO, Dr. Sean Tucker, SVP and Chief Scientific
Officer, and Dr. James Cummings, Chief Medical Officer, will be
participating in virtual fireside chats at the following
conferences:
- Jefferies London Healthcare
ConferenceThe fireside chat will be available to view
on-demand beginning Thursday, November 18 at 8:00 a.m. GMT / 3:00
a.m. ET.
-
33rd Annual Piper Sandler
Healthcare ConferenceThe fireside chat will be available
to view on-demand beginning Monday, November 22 at 10:00 a.m.
ET.
Webcasts of both fireside chats will be
available on the Company’s Events & Presentations page,
accessible here: https://investors.vaxart.com/events-presentations.
Replays will also be available on the Company’s website following
each event. The Company will also participate in one-on-one
meetings during the conferences.
Vaxart’s oral tablet COVID-19 vaccine is the
only oral COVID-19 vaccine whose potential is backed by clinical
data, and it is the only one in Phase II clinical trials, which
started in October 2021.
About VaxartVaxart is a
clinical-stage biotechnology company developing a range of oral
recombinant vaccines based on its proprietary delivery platform.
Vaxart vaccines are designed to be administered using tablets that
can be stored and shipped without refrigeration and eliminate the
risk of needle-stick injury. Vaxart believes that its proprietary
tablet vaccine delivery platform is suitable to deliver recombinant
vaccines, positioning the company to develop oral versions of
currently marketed vaccines and to design recombinant vaccines for
new indications. Vaxart's development programs currently include
tablet vaccines designed to protect against coronavirus, norovirus,
seasonal influenza, and respiratory syncytial virus (RSV), as well
as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's
first immuno-oncology indication. Vaxart has filed broad domestic
and international patent applications covering its proprietary
technology and creations for oral vaccination using adenovirus and
TLR3 agonists.
Note Regarding Forward-Looking
Statements This press release contains
forward-looking statements that involve substantial risks and
uncertainties. All statements, other than statements of historical
facts, included in this press release regarding Vaxart's strategy,
prospects, plans and objectives, results from pre-clinical and
clinical trials, commercialization agreements and licenses, and
beliefs and expectations of management are forward-looking
statements. These forward-looking statements may be accompanied by
such words as "should," "believe," "could," "potential," "will,"
"expected," "plan," and other words and terms of similar meaning.
Examples of such statements include, but are not limited to,
statements relating to the receipt by Vaxart's ability to develop
and commercialize its product candidates, including its vaccine
booster products; Vaxart's expectations regarding clinical results
and trial data; and Vaxart's expectations with respect to the
effectiveness of its product candidates. Vaxart may not actually
achieve the plans, carry out the intentions, or meet the
expectations or projections disclosed in the forward-looking
statements, and you should not place undue reliance on these
forward-looking statements. Actual results or events could differ
materially from the plans, intentions, expectations, and
projections disclosed in the forward-looking statements. Various
important factors could cause actual results or events to differ
materially from the forward-looking statements that Vaxart makes,
including uncertainties inherent in research and development,
including the ability to meet anticipated clinical endpoints,
commencement, and/or completion dates for clinical trials,
regulatory submission dates, regulatory approval dates, and/or
launch dates, as well as the possibility of unfavorable new
clinical data and further analyses of existing clinical data; the
risk that clinical trial data are subject to differing
interpretations and assessments by regulatory authorities;
whether regulatory authorities will be satisfied with the
design of and results from the clinical studies; decisions by
regulatory authorities impacting labeling, manufacturing processes,
and safety that could affect the availability or commercial
potential of any product candidate, including the possibility that
Vaxart's product candidates may not be approved by the FDA or
non-U.S. regulatory authorities; that, even if approved by the FDA
or non-U.S. regulatory authorities, Vaxart's product candidates may
not achieve broad market acceptance; that a Vaxart collaborator may
not attain development and commercial milestones; that Vaxart or
its partners may experience manufacturing issues and delays due to
events within, or outside of, Vaxart's or its partners' control;
difficulties in production, particularly in scaling up initial
production, including difficulties with production costs and
yields, quality control, including stability of the product
candidate and quality assurance testing, shortages of qualified
personnel or key raw materials, and compliance with strictly
enforced federal, state, and foreign regulations; that Vaxart may
not be able to obtain, maintain, and enforce necessary patent and
other intellectual property protection; that Vaxart's capital
resources may be inadequate; Vaxart's ability to resolve pending
legal matters; Vaxart's ability to obtain sufficient capital to
fund its operations on terms acceptable to Vaxart, if at all; the
impact of government healthcare proposals and policies; competitive
factors; and other risks described in the "Risk Factors" sections
of Vaxart's Quarterly and Annual Reports filed with the SEC. Vaxart
does not assume any obligation to update any forward-looking
statements, except as required by law.
Contacts
Vaxart Media Relations: |
Investor Relations: |
Mark Herr |
Andrew Blazier |
Vaxart, Inc. |
FINN Partners |
mherr@vaxart.com |
IR@vaxart.com |
(203) 517-8957 |
(646)
871-8486 |
Vaxart (NASDAQ:VXRT)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Vaxart (NASDAQ:VXRT)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024